Skip to content

Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to Radiotherapy

Mepitel Film vs Standard of Care for the Radiotherapy Prevention and Cutaneous Toxicity in Patients With Post-surgery Breast Cancer

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02741258
Enrollment
164
Registered
2016-04-18
Start date
2015-10-01
Completion date
2021-12-31
Last updated
2022-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-surgery Radiotherapy

Brief summary

This is a randomized study, mepitel vs standard of care for the prevention and skin toxicity due to radiotherapy in patients with post-surgery breast cancer. Mepitel film will be placed on the skin of the patients just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of toxicities.

Detailed description

For patients randomized in the mepitel arm: Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with mepitel. For patients randomized in the standard of treatment arm: Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine o Ialugen Plus) cream in case of skin erythema. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.

Interventions

Placement of Mepitel Film to prevent skin toxicity

DRUGskin cream

cream to treat skin erythema due to radiotherapy

Sponsors

Dario Valcarenghi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with breast cancer treated with conservative surgery who need radiotherapy treatment * capability and willness to participate to the study * informed consent form signature

Exclusion criteria

* contraindication to the correct placement of the Mepitel Film * previous breast radiation treatment * participating in other clinical trials * previous breast reconstruction * concomitant treatment with antiblastic chemotherapy

Design outcomes

Primary

MeasureTime frameDescription
Mepitel Film efficacy in treating skin toxicity evaluatet with Common Terminology Criteria for Adverse Events (CTCAE)one week after start of radiotherapyCommon Terminology Criteria for Adverse Events (CTCAE) V.4 will be used to evaluate the toxicity

Secondary

MeasureTime frameDescription
Time for the skin toxicity appearance and resolutionone week after start of radiotherapy
Severity of the chronic skin toxicityone week after start of radiotherapyCommon Terminology Criteria for Adverse Events (CTCAE) v.4

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026